Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury
Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibi...
Gespeichert in:
Veröffentlicht in: | Journal of cellular physiology 2021-04, Vol.236 (4), p.2893-2905 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2905 |
---|---|
container_issue | 4 |
container_start_page | 2893 |
container_title | Journal of cellular physiology |
container_volume | 236 |
creator | Kovacs‐Kasa, Anita Kovacs, Laszlo Cherian‐Shaw, Mary Patel, Vijay Meadows, Mary L. Fulton, David J. Su, Yunchao Verin, Alexander D. |
description | Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibitors for the treatment of cardiovascular and inflammatory diseases is increasingly apparent, but the mechanisms by which HDACs regulate pulmonary vascular barrier function remain to be resolved. We found that specific Class IIa HDACs inhibitor, TMP269, significantly attenuated the lipopolysaccharide (LPS)‐induced human lung microvascular endothelial cells (HLMVEC) barrier compromise in vitro and improved vascular barrier integrity and lung function in murine model of ALI in vivo. TMP269 decreased LPS‐induced myosin light chain phosphorylation suggesting the role for Class IIa HDACs in LPS‐induced cytoskeleton reorganization. TMP269 did not affect microtubule structure and tubulin acetylation in contrast to the HDAC6‐specific inhibitor, Tubastatin A suggesting that Class IIa HDACs and HDAC6 (Class IIb) regulate endothelial cytoskeleton and permeability via different mechanisms. Furthermore, LPS increased the expression of ArgBP2 which has recently been attributed to HDAC‐mediated activation of Rho. Depletion of ArgBP2 abolished the ability of LPS to disrupt barrier function in HLMVEC and both TMP269 and Tubastatin A decreased the level of ArgBP2 expression after LPS stimulation suggesting that both Class IIa and IIb HDACs regulate endothelial permeability via ArgBP2‐dependent mechanism. Collectively, our data strongly suggest that Class IIa HDACs are involved in LPS‐induced ALI in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.
Class IIa histone deacetylases are involved in lipopolysaccharide‐induced acute lung injury in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization. |
doi_str_mv | 10.1002/jcp.30053 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jcp_30053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2488831038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4433-b788e0ef5b7e7b5b8781a037b5c7322c90085f19fd7fee4bf8d753c2be6f6a993</originalsourceid><addsrcrecordid>eNp1kUFvFCEYhonR2LV68A8YEk8epoVh2IGLSTNqu02TetAzAeajy2YWVphp3Zs_wd_oL5F22kYPPUHyPjx8X16E3lJyRAmpjzd2d8QI4ewZWlAi26pZ8vo5WpSMVpI39AC9ynlDCJGSsZfogNWSSyH5Ag2rsPbGjz4GHB3uBp0zXq00Pvt00mXst7sUryFjCH0c1zB4PWCjU_KQsJuCvXvow5zHnz78-fXbh36y0GNtpxHwMIWrQmymtH-NXjg9ZHhzfx6i718-f-vOqovL01V3clHZpmGsMq0QQMBx00JruBGtoJqwcrUtq2srCRHcUen61gE0xom-5czWBpZuqcuKh-jj7N1NZgu9hTAmPahd8lud9ipqr_5Pgl-rq3itpGyWlNEieH8vSPHHBHlUmzilUGZWdSOEYJQwUagPM2VTzDmBe_yBEnVbjCrFqLtiCvvu35EeyYcmCnA8Azd-gP3TJnXefZ2VfwHRhJre</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2488831038</pqid></control><display><type>article</type><title>Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Kovacs‐Kasa, Anita ; Kovacs, Laszlo ; Cherian‐Shaw, Mary ; Patel, Vijay ; Meadows, Mary L. ; Fulton, David J. ; Su, Yunchao ; Verin, Alexander D.</creator><creatorcontrib>Kovacs‐Kasa, Anita ; Kovacs, Laszlo ; Cherian‐Shaw, Mary ; Patel, Vijay ; Meadows, Mary L. ; Fulton, David J. ; Su, Yunchao ; Verin, Alexander D.</creatorcontrib><description>Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibitors for the treatment of cardiovascular and inflammatory diseases is increasingly apparent, but the mechanisms by which HDACs regulate pulmonary vascular barrier function remain to be resolved. We found that specific Class IIa HDACs inhibitor, TMP269, significantly attenuated the lipopolysaccharide (LPS)‐induced human lung microvascular endothelial cells (HLMVEC) barrier compromise in vitro and improved vascular barrier integrity and lung function in murine model of ALI in vivo. TMP269 decreased LPS‐induced myosin light chain phosphorylation suggesting the role for Class IIa HDACs in LPS‐induced cytoskeleton reorganization. TMP269 did not affect microtubule structure and tubulin acetylation in contrast to the HDAC6‐specific inhibitor, Tubastatin A suggesting that Class IIa HDACs and HDAC6 (Class IIb) regulate endothelial cytoskeleton and permeability via different mechanisms. Furthermore, LPS increased the expression of ArgBP2 which has recently been attributed to HDAC‐mediated activation of Rho. Depletion of ArgBP2 abolished the ability of LPS to disrupt barrier function in HLMVEC and both TMP269 and Tubastatin A decreased the level of ArgBP2 expression after LPS stimulation suggesting that both Class IIa and IIb HDACs regulate endothelial permeability via ArgBP2‐dependent mechanism. Collectively, our data strongly suggest that Class IIa HDACs are involved in LPS‐induced ALI in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.
Class IIa histone deacetylases are involved in lipopolysaccharide‐induced acute lung injury in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.</description><identifier>ISSN: 0021-9541</identifier><identifier>EISSN: 1097-4652</identifier><identifier>DOI: 10.1002/jcp.30053</identifier><identifier>PMID: 32959895</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acetylation ; acute lung injury ; Acute Lung Injury - chemically induced ; Acute Lung Injury - enzymology ; Acute Lung Injury - physiopathology ; Adaptor Proteins, Signal Transducing - metabolism ; Animal models ; Animals ; barrier protection ; Cell Membrane Permeability - drug effects ; Class IIA HDACs inhibition ; Contractility ; Cytoskeleton ; Depletion ; Disease Models, Animal ; Endothelial cells ; Endothelial Cells - drug effects ; Endothelial Cells - metabolism ; Endotoxins ; Heart Rate - drug effects ; Histone deacetylase ; Histone Deacetylase Inhibitors - pharmacology ; Histone Deacetylases - metabolism ; Inflammatory diseases ; Inhibitors ; Lipopolysaccharides ; LPS ; Lung - drug effects ; Lung - pathology ; Lung - physiopathology ; Lungs ; Mice ; Mice, Inbred C57BL ; Microvasculature ; Microvessels - pathology ; Models, Biological ; Myosin ; Oxygen - metabolism ; Permeability ; Phosphorylation ; Pneumonia - complications ; Pneumonia - pathology ; pulmonary endothelium ; Respiratory function ; rho GTP-Binding Proteins - metabolism ; Signal Transduction - drug effects ; TMP269 ; Tubulin</subject><ispartof>Journal of cellular physiology, 2021-04, Vol.236 (4), p.2893-2905</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><rights>2021 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4433-b788e0ef5b7e7b5b8781a037b5c7322c90085f19fd7fee4bf8d753c2be6f6a993</citedby><cites>FETCH-LOGICAL-c4433-b788e0ef5b7e7b5b8781a037b5c7322c90085f19fd7fee4bf8d753c2be6f6a993</cites><orcidid>0000-0003-0627-7185 ; 0000-0001-7244-5517</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcp.30053$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcp.30053$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32959895$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kovacs‐Kasa, Anita</creatorcontrib><creatorcontrib>Kovacs, Laszlo</creatorcontrib><creatorcontrib>Cherian‐Shaw, Mary</creatorcontrib><creatorcontrib>Patel, Vijay</creatorcontrib><creatorcontrib>Meadows, Mary L.</creatorcontrib><creatorcontrib>Fulton, David J.</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Verin, Alexander D.</creatorcontrib><title>Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury</title><title>Journal of cellular physiology</title><addtitle>J Cell Physiol</addtitle><description>Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibitors for the treatment of cardiovascular and inflammatory diseases is increasingly apparent, but the mechanisms by which HDACs regulate pulmonary vascular barrier function remain to be resolved. We found that specific Class IIa HDACs inhibitor, TMP269, significantly attenuated the lipopolysaccharide (LPS)‐induced human lung microvascular endothelial cells (HLMVEC) barrier compromise in vitro and improved vascular barrier integrity and lung function in murine model of ALI in vivo. TMP269 decreased LPS‐induced myosin light chain phosphorylation suggesting the role for Class IIa HDACs in LPS‐induced cytoskeleton reorganization. TMP269 did not affect microtubule structure and tubulin acetylation in contrast to the HDAC6‐specific inhibitor, Tubastatin A suggesting that Class IIa HDACs and HDAC6 (Class IIb) regulate endothelial cytoskeleton and permeability via different mechanisms. Furthermore, LPS increased the expression of ArgBP2 which has recently been attributed to HDAC‐mediated activation of Rho. Depletion of ArgBP2 abolished the ability of LPS to disrupt barrier function in HLMVEC and both TMP269 and Tubastatin A decreased the level of ArgBP2 expression after LPS stimulation suggesting that both Class IIa and IIb HDACs regulate endothelial permeability via ArgBP2‐dependent mechanism. Collectively, our data strongly suggest that Class IIa HDACs are involved in LPS‐induced ALI in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.
Class IIa histone deacetylases are involved in lipopolysaccharide‐induced acute lung injury in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.</description><subject>Acetylation</subject><subject>acute lung injury</subject><subject>Acute Lung Injury - chemically induced</subject><subject>Acute Lung Injury - enzymology</subject><subject>Acute Lung Injury - physiopathology</subject><subject>Adaptor Proteins, Signal Transducing - metabolism</subject><subject>Animal models</subject><subject>Animals</subject><subject>barrier protection</subject><subject>Cell Membrane Permeability - drug effects</subject><subject>Class IIA HDACs inhibition</subject><subject>Contractility</subject><subject>Cytoskeleton</subject><subject>Depletion</subject><subject>Disease Models, Animal</subject><subject>Endothelial cells</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - metabolism</subject><subject>Endotoxins</subject><subject>Heart Rate - drug effects</subject><subject>Histone deacetylase</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Histone Deacetylases - metabolism</subject><subject>Inflammatory diseases</subject><subject>Inhibitors</subject><subject>Lipopolysaccharides</subject><subject>LPS</subject><subject>Lung - drug effects</subject><subject>Lung - pathology</subject><subject>Lung - physiopathology</subject><subject>Lungs</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microvasculature</subject><subject>Microvessels - pathology</subject><subject>Models, Biological</subject><subject>Myosin</subject><subject>Oxygen - metabolism</subject><subject>Permeability</subject><subject>Phosphorylation</subject><subject>Pneumonia - complications</subject><subject>Pneumonia - pathology</subject><subject>pulmonary endothelium</subject><subject>Respiratory function</subject><subject>rho GTP-Binding Proteins - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>TMP269</subject><subject>Tubulin</subject><issn>0021-9541</issn><issn>1097-4652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFvFCEYhonR2LV68A8YEk8epoVh2IGLSTNqu02TetAzAeajy2YWVphp3Zs_wd_oL5F22kYPPUHyPjx8X16E3lJyRAmpjzd2d8QI4ewZWlAi26pZ8vo5WpSMVpI39AC9ynlDCJGSsZfogNWSSyH5Ag2rsPbGjz4GHB3uBp0zXq00Pvt00mXst7sUryFjCH0c1zB4PWCjU_KQsJuCvXvow5zHnz78-fXbh36y0GNtpxHwMIWrQmymtH-NXjg9ZHhzfx6i718-f-vOqovL01V3clHZpmGsMq0QQMBx00JruBGtoJqwcrUtq2srCRHcUen61gE0xom-5czWBpZuqcuKh-jj7N1NZgu9hTAmPahd8lud9ipqr_5Pgl-rq3itpGyWlNEieH8vSPHHBHlUmzilUGZWdSOEYJQwUagPM2VTzDmBe_yBEnVbjCrFqLtiCvvu35EeyYcmCnA8Azd-gP3TJnXefZ2VfwHRhJre</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Kovacs‐Kasa, Anita</creator><creator>Kovacs, Laszlo</creator><creator>Cherian‐Shaw, Mary</creator><creator>Patel, Vijay</creator><creator>Meadows, Mary L.</creator><creator>Fulton, David J.</creator><creator>Su, Yunchao</creator><creator>Verin, Alexander D.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0627-7185</orcidid><orcidid>https://orcid.org/0000-0001-7244-5517</orcidid></search><sort><creationdate>202104</creationdate><title>Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury</title><author>Kovacs‐Kasa, Anita ; Kovacs, Laszlo ; Cherian‐Shaw, Mary ; Patel, Vijay ; Meadows, Mary L. ; Fulton, David J. ; Su, Yunchao ; Verin, Alexander D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4433-b788e0ef5b7e7b5b8781a037b5c7322c90085f19fd7fee4bf8d753c2be6f6a993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acetylation</topic><topic>acute lung injury</topic><topic>Acute Lung Injury - chemically induced</topic><topic>Acute Lung Injury - enzymology</topic><topic>Acute Lung Injury - physiopathology</topic><topic>Adaptor Proteins, Signal Transducing - metabolism</topic><topic>Animal models</topic><topic>Animals</topic><topic>barrier protection</topic><topic>Cell Membrane Permeability - drug effects</topic><topic>Class IIA HDACs inhibition</topic><topic>Contractility</topic><topic>Cytoskeleton</topic><topic>Depletion</topic><topic>Disease Models, Animal</topic><topic>Endothelial cells</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - metabolism</topic><topic>Endotoxins</topic><topic>Heart Rate - drug effects</topic><topic>Histone deacetylase</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Histone Deacetylases - metabolism</topic><topic>Inflammatory diseases</topic><topic>Inhibitors</topic><topic>Lipopolysaccharides</topic><topic>LPS</topic><topic>Lung - drug effects</topic><topic>Lung - pathology</topic><topic>Lung - physiopathology</topic><topic>Lungs</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microvasculature</topic><topic>Microvessels - pathology</topic><topic>Models, Biological</topic><topic>Myosin</topic><topic>Oxygen - metabolism</topic><topic>Permeability</topic><topic>Phosphorylation</topic><topic>Pneumonia - complications</topic><topic>Pneumonia - pathology</topic><topic>pulmonary endothelium</topic><topic>Respiratory function</topic><topic>rho GTP-Binding Proteins - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>TMP269</topic><topic>Tubulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kovacs‐Kasa, Anita</creatorcontrib><creatorcontrib>Kovacs, Laszlo</creatorcontrib><creatorcontrib>Cherian‐Shaw, Mary</creatorcontrib><creatorcontrib>Patel, Vijay</creatorcontrib><creatorcontrib>Meadows, Mary L.</creatorcontrib><creatorcontrib>Fulton, David J.</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Verin, Alexander D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cellular physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kovacs‐Kasa, Anita</au><au>Kovacs, Laszlo</au><au>Cherian‐Shaw, Mary</au><au>Patel, Vijay</au><au>Meadows, Mary L.</au><au>Fulton, David J.</au><au>Su, Yunchao</au><au>Verin, Alexander D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury</atitle><jtitle>Journal of cellular physiology</jtitle><addtitle>J Cell Physiol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>236</volume><issue>4</issue><spage>2893</spage><epage>2905</epage><pages>2893-2905</pages><issn>0021-9541</issn><eissn>1097-4652</eissn><abstract>Acute lung injury (ALI) is an acute inflammatory process arises from a wide range of lung insults. A major cause of ALI is dysfunction of the pulmonary vascular endothelial barrier but the mechanisms involved are incompletely understood. The therapeutic potential of histone deacetylase (HDAC) inhibitors for the treatment of cardiovascular and inflammatory diseases is increasingly apparent, but the mechanisms by which HDACs regulate pulmonary vascular barrier function remain to be resolved. We found that specific Class IIa HDACs inhibitor, TMP269, significantly attenuated the lipopolysaccharide (LPS)‐induced human lung microvascular endothelial cells (HLMVEC) barrier compromise in vitro and improved vascular barrier integrity and lung function in murine model of ALI in vivo. TMP269 decreased LPS‐induced myosin light chain phosphorylation suggesting the role for Class IIa HDACs in LPS‐induced cytoskeleton reorganization. TMP269 did not affect microtubule structure and tubulin acetylation in contrast to the HDAC6‐specific inhibitor, Tubastatin A suggesting that Class IIa HDACs and HDAC6 (Class IIb) regulate endothelial cytoskeleton and permeability via different mechanisms. Furthermore, LPS increased the expression of ArgBP2 which has recently been attributed to HDAC‐mediated activation of Rho. Depletion of ArgBP2 abolished the ability of LPS to disrupt barrier function in HLMVEC and both TMP269 and Tubastatin A decreased the level of ArgBP2 expression after LPS stimulation suggesting that both Class IIa and IIb HDACs regulate endothelial permeability via ArgBP2‐dependent mechanism. Collectively, our data strongly suggest that Class IIa HDACs are involved in LPS‐induced ALI in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.
Class IIa histone deacetylases are involved in lipopolysaccharide‐induced acute lung injury in vitro and in vivo via specific mechanism which involved contractile responses, but not microtubule reorganization.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32959895</pmid><doi>10.1002/jcp.30053</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-0627-7185</orcidid><orcidid>https://orcid.org/0000-0001-7244-5517</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9541 |
ispartof | Journal of cellular physiology, 2021-04, Vol.236 (4), p.2893-2905 |
issn | 0021-9541 1097-4652 |
language | eng |
recordid | cdi_crossref_primary_10_1002_jcp_30053 |
source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
subjects | Acetylation acute lung injury Acute Lung Injury - chemically induced Acute Lung Injury - enzymology Acute Lung Injury - physiopathology Adaptor Proteins, Signal Transducing - metabolism Animal models Animals barrier protection Cell Membrane Permeability - drug effects Class IIA HDACs inhibition Contractility Cytoskeleton Depletion Disease Models, Animal Endothelial cells Endothelial Cells - drug effects Endothelial Cells - metabolism Endotoxins Heart Rate - drug effects Histone deacetylase Histone Deacetylase Inhibitors - pharmacology Histone Deacetylases - metabolism Inflammatory diseases Inhibitors Lipopolysaccharides LPS Lung - drug effects Lung - pathology Lung - physiopathology Lungs Mice Mice, Inbred C57BL Microvasculature Microvessels - pathology Models, Biological Myosin Oxygen - metabolism Permeability Phosphorylation Pneumonia - complications Pneumonia - pathology pulmonary endothelium Respiratory function rho GTP-Binding Proteins - metabolism Signal Transduction - drug effects TMP269 Tubulin |
title | Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A28%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20Class%20IIa%20HDACs%20improves%20endothelial%20barrier%20function%20in%20endotoxin%E2%80%90induced%20acute%20lung%20injury&rft.jtitle=Journal%20of%20cellular%20physiology&rft.au=Kovacs%E2%80%90Kasa,%20Anita&rft.date=2021-04&rft.volume=236&rft.issue=4&rft.spage=2893&rft.epage=2905&rft.pages=2893-2905&rft.issn=0021-9541&rft.eissn=1097-4652&rft_id=info:doi/10.1002/jcp.30053&rft_dat=%3Cproquest_pubme%3E2488831038%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2488831038&rft_id=info:pmid/32959895&rfr_iscdi=true |